HepaRegeniX
Small molecule MKK4 inhibitors to treat acute and chronic liver diseases
3
Funding Rounds
$37.6m
Money raised
Overview
Small molecule MKK4 inhibitors to treat acute and chronic liver diseases
- Website:
- Social accounts: linkedin
Funding
Funding series
Funding Series Analysis
The company HepaRegeniX has raised a total of $37.6m in funding over 3 rounds.
Key Insights:
- HepaRegeniX July 2024 Series C Funding Round: $16m
- HepaRegeniX Series B round, January 2020: $12.1m
- HepaRegeniX Series A round, January 2017: $9.5m
HepaRegeniX July 2024 Series C Funding Round
$16m
HepaRegeniX Series B round, January 2020
$12.1m
HepaRegeniX Series A round, January 2017
$9.5m
Industries
HepaRegeniX is active in the following industries: